1. Immunology and Inflammation

Ascorbic acid supports ex vivo generation of plasmacytoid dendritic cells from circulating hematopoietic stem cells

  1. Anders Laustsen
  2. Renée M van der Sluis
  3. Albert Gris-Oliver
  4. Sabina Sánchez Hernández
  5. Ena Cemalovic
  6. Hai Q Tang
  7. Lars Henning Pedersen
  8. Niels Uldbjerg
  9. Martin R Jakobsen  Is a corresponding author
  10. Rasmus O Bak  Is a corresponding author
  1. Aarhus University, Denmark
  2. Aarhus University Hospital, Denmark
  3. niels uldbjerg, Denmark
https://doi.org/10.7554/eLife.65528
Share this article
Cite this article
  1. Anders Laustsen
  2. Renée M van der Sluis
  3. Albert Gris-Oliver
  4. Sabina Sánchez Hernández
  5. Ena Cemalovic
  6. Hai Q Tang
  7. Lars Henning Pedersen
  8. Niels Uldbjerg
  9. Martin R Jakobsen
  10. Rasmus O Bak
(2021)
Ascorbic acid supports ex vivo generation of plasmacytoid dendritic cells from circulating hematopoietic stem cells
eLife 10:e65528.
https://doi.org/10.7554/eLife.65528
  2. Download BibTeX
  3. Download .RIS

Abstract

Plasmacytoid dendritic cells (pDCs) constitute a rare type of immune cell with multifaceted functions, but their potential use as a cell-based immunotherapy is challenged by the scarce cell numbers that can be extracted from blood. Here, we systematically investigate culture parameters for generating pDCs from hematopoietic stem and progenitor cells (HSPCs). Using optimized conditions combined with implementation of HSPC pre-expansion, we generate an average of 465 million HSPC-derived pDCs (HSPC-pDCs) starting from 100,000 cord blood-derived HSPCs. Furthermore, we demonstrate that such protocol allows HSPC-pDC generation from whole blood HSPCs, and these cells display a pDC phenotype and function. Using GMP compliant medium, we observe a remarkable loss of TLR7/9 responses, which is rescued by ascorbic acid supplementation. Ascorbic acid induces transcriptional signatures associated with pDC-specific innate immune pathways suggesting an undescribed role of ascorbic acid for pDC functionality. This constitutes the first protocol for generating pDCs from whole blood, and lay the foundation for investigating HSPC-pDCs for cell-based immunotherapy.

Data availability

All data generated or analysed during this study are included in the manuscript and supporting files. Sequencing data have been deposited in Dryad (doi:10.5061/dryad.69p8cz92z).

The following data sets were generated

Article and author information

Author details

  1. Anders Laustsen

    Department of Biomedicine, Aarhus University, Aarhus, Denmark
    Competing interests
    Anders Laustsen, Aarhus University has filed a patent related to this work with AL, MRJ, and ROB as co-inventors. AL, MRJ and ROB hold equity in the Danish company UNIKUM Therapeutics ApS. Part-time employees of UNIKUM Therapeutics ApS..

  2. Renée M van der Sluis

    Department of Biomedicine, Aarhus University, Aarhus C., Denmark
    Competing interests
    No competing interests declared.

  3. Albert Gris-Oliver

    Department of Biomedicine, Aarhus University, Aarhus, Denmark
    Competing interests
    No competing interests declared.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0003-1802-9541

  4. Sabina Sánchez Hernández

    Department of Biomedicine, Aarhus University, Aarhus, Denmark
    Competing interests
    No competing interests declared.

  5. Ena Cemalovic

    Department of Biomedicine, Aarhus University, Aarhus, Denmark
    Competing interests
    No competing interests declared.

  6. Hai Q Tang

    Department of Obstetrics and Gynaecology, Aarhus University Hospital, Aarhus N., Denmark
    Competing interests
    No competing interests declared.

  7. Lars Henning Pedersen

    Department of Obstetrics and Gynaecology, Aarhus University Hospital, Aarhus N., Denmark
    Competing interests
    No competing interests declared.

  8. Niels Uldbjerg

    Department of Clinical Medicine, niels uldbjerg, Aarhus V, Denmark
    Competing interests
    No competing interests declared.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-6449-6426

  9. Martin R Jakobsen

    Department of Biomedicine, Aarhus University, Aarhus, Denmark
    For correspondence
    mrj@biomed.au.dk
    Competing interests
    Martin R Jakobsen, Aarhus University has filed a patent related to this work with AL, MRJ, and ROB as co-inventors. AL, MRJ and ROB hold equity in the Danish company UNIKUM Therapeutics ApS. Serves on the board of directors of UNIKUM Therapeutics ApS..

  10. Rasmus O Bak

    Department of Biomedicine, Aarhus University, Aarhus C., Denmark
    For correspondence
    bak@biomed.au.dk
    Competing interests
    Rasmus O Bak, Aarhus University has filed a patent related to this work with AL, MRJ, and ROB as co-inventors. AL, MRJ and ROB hold equity in the Danish company UNIKUM Therapeutics ApS. Part-time employees of UNIKUM Therapeutics ApS. Holds equity in Graphite Bio..
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-7383-0297

Funding

Lundbeckfonden (R238-2016-3349)

  • Rasmus O Bak

Aarhus Institute of Advanced Studies, Aarhus Universitet

  • Renée M van der Sluis
  • Rasmus O Bak

European Union (609033)

  • Rasmus O Bak

Lundbeckfonden (R238-2016-2708)

  • Martin R Jakobsen

Independent Research Fund Denmark (8020-00201B)

  • Martin R Jakobsen

Novo Nordisk Fonden (NNF18OC0053146)

  • Martin R Jakobsen

European Union (754513)

  • Renée M van der Sluis

Carlsbergfondet (CF17-0129)

  • Rasmus O Bak

Carlsbergfondet (CF20-0424)

  • Rasmus O Bak

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Ethics

Human subjects: De-identified umbilical cord blood (UCB) samples were obtained following scheduled caesarean section deliveries of healthy infants at Department of Gynecology and Obstetrics, Skejby University Hospital. Consent was obtained from the mothers, but studies on anonymized samples, such as those used in the present study, are exempt from ethical permissions in Denmark (Kommiteeloven {section sign} {section sign}14. 3).Buffy coat samples were obtained from normal healthy donors from Aarhus University Hospital Blood Bank. These were de-identified samples and studies on anonymized samples are exempt from ethical permissions in Denmark (Kommiteeloven {section sign} {section sign}14. 3).

Copyright

© 2021, Laustsen et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 1,851
    views
  • 265
    downloads
  • 9
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Anders Laustsen
  2. Renée M van der Sluis
  3. Albert Gris-Oliver
  4. Sabina Sánchez Hernández
  5. Ena Cemalovic
  6. Hai Q Tang
  7. Lars Henning Pedersen
  8. Niels Uldbjerg
  9. Martin R Jakobsen
  10. Rasmus O Bak
(2021)
Ascorbic acid supports ex vivo generation of plasmacytoid dendritic cells from circulating hematopoietic stem cells
eLife 10:e65528.
https://doi.org/10.7554/eLife.65528

Share this article

https://doi.org/10.7554/eLife.65528

Categories and tags

Research organism

Further reading

    1. Immunology and Inflammation

    Role of hepatocyte RIPK1 in maintaining liver homeostasis during metabolic challenges

    Weigao Zhang, Hu Liu ... Dan Weng
    Research Article

    As a central hub for metabolism, the liver exhibits strong adaptability to maintain homeostasis in response to food fluctuations throughout evolution. However, the mechanisms governing this resilience remain incompletely understood. In this study, we identified Receptor interacting protein kinase 1 (RIPK1) in hepatocytes as a critical regulator in preserving hepatic homeostasis during metabolic challenges, such as short-term fasting or high-fat dieting. Our results demonstrated that hepatocyte-specific deficiency of RIPK1 sensitized the liver to short-term fasting-induced liver injury and hepatocyte apoptosis in both male and female mice. Despite being a common physiological stressor that typically does not induce liver inflammation, short-term fasting triggered hepatic inflammation and compensatory proliferation in hepatocyte-specific RIPK1-deficient (Ripk1-hepKO) mice. Transcriptomic analysis revealed that short-term fasting oriented the hepatic microenvironment into an inflammatory state in Ripk1-hepKO mice, with up-regulated expression of inflammation and immune cell recruitment-associated genes. Single-cell RNA sequencing further confirmed the altered cellular composition in the liver of Ripk1-hepKO mice during fasting, highlighting the increased recruitment of macrophages to the liver. Mechanically, our results indicated that ER stress was involved in fasting-induced liver injury in Ripk1-hepKO mice. Overall, our findings revealed the role of RIPK1 in maintaining liver homeostasis during metabolic fluctuations and shed light on the intricate interplay between cell death, inflammation, and metabolism.

    1. Immunology and Inflammation

    Syngeneic natural killer cell therapy activates dendritic and T cells in metastatic lungs and effectively treats low-burden metastases

    Shih-Wen Huang, Yein-Gei Lai ... Nan-Shih Liao
    Research Article

    Natural killer (NK) cells can control metastasis through cytotoxicity and IFN-γ production independently of T cells in experimental metastasis mouse models. The inverse correlation between NK activity and metastasis incidence supports a critical role for NK cells in human metastatic surveillance. However, autologous NK cell therapy has shown limited benefit in treating patients with metastatic solid tumors. Using a spontaneous metastasis mouse model of MHC-I+ breast cancer, we found that transfer of IL-15/IL-12-conditioned syngeneic NK cells after primary tumor resection promoted long-term survival of mice with low metastatic burden and induced a tumor-specific protective T cell response that is essential for the therapeutic effect. Furthermore, NK cell transfer augments activation of conventional dendritic cells (cDCs), Foxp3-CD4+ T cells and stem cell-like CD8+ T cells in metastatic lungs, to which IFN-γ of the transferred NK cells contributes significantly. These results imply direct interactions between transferred NK cells and endogenous cDCs to enhance T cell activation. We conducted an investigator-initiated clinical trial of autologous NK cell therapy in six patients with advanced cancer and observed that the NK cell therapy was safe and showed signs of effectiveness. These findings indicate that autologous NK cell therapy is effective in treating established low burden metastases of MHC-I+ tumor cells by activating the cDC-T cell axis at metastatic sites.

    1. Genetics and Genomics
    2. Immunology and Inflammation

    Paradoxical dominant negative activity of an immunodeficiency-associated activating PIK3R1 variant

    Patsy R Tomlinson, Rachel G Knox ... Robert K Semple
    Research Article

    PIK3R1 encodes three regulatory subunits of class IA phosphoinositide 3-kinase (PI3K), each associating with any of three catalytic subunits, namely p110α, p110β, or p110δ. Constitutional PIK3R1 mutations cause diseases with a genotype-phenotype relationship not yet fully explained: heterozygous loss-of-function mutations cause SHORT syndrome, featuring insulin resistance and short stature attributed to reduced p110α function, while heterozygous activating mutations cause immunodeficiency, attributed to p110δ activation and known as APDS2. Surprisingly, APDS2 patients do not show features of p110α hyperactivation, but do commonly have SHORT syndrome-like features, suggesting p110α hypofunction. We sought to investigate this. In dermal fibroblasts from an APDS2 patient, we found no increased PI3K signalling, with p110δ expression markedly reduced. In preadipocytes, the APDS2 variant was potently dominant negative, associating with Irs1 and Irs2 but failing to heterodimerise with p110α. This attenuation of p110α signalling by a p110δ-activating PIK3R1 variant potentially explains co-incidence of gain-of-function and loss-of-function PIK3R1 phenotypes.